BI26 HIV-associated sarcoidosis as a manifestation of immune reconstitution inflammatory syndrome
Sophie Diong,Pranav Gnanamoorthy,Michéal O’Rourke,Joanne Byrne,Colm Bergin,Mairin McMenamin,Bairbre Wynne
DOI: https://doi.org/10.1093/bjd/ljae090.314
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract In up to 30% of patients with HIV treated with highly active antiretroviral therapy (HAART), paradoxical reactions occur following immune system recovery, with improvements in CD4 counts and resultant T-helper responses to inflammation – a process known as immune reconstitution inflammatory syndrome (IRIS). Sarcoidosis, a T-helper-cell-mediated disease, has been associated with this state. We present a case of HIV-associated sarcoidosis as a manifestation of IRIS. A 47-year-old South African female patient with HIV and pulmonary sarcoidosis reported a 3-month history of a new rash. She acknowledged intermittent compliance with HAART 8 months prior. Examination revealed an erythematous papular eruption affecting her face and upper extremities. Interferon-γ release assay was negative. Serum angiotensin-converting enzyme was elevated. Serum soluble interleukin-2 receptor was normal, perhaps due to underlying HIV diagnosis. Initial biopsy highlighted non-necrotizing granulomas in keeping with sarcoidosis. Five months later, following a further period of poor HAART compliance, the eruption was more florid, associated with nasal congestion and xerophthalmia. Examination revealed multiple erythematous indurated nodulopapular lesions affecting her nasal bridge, bilateral cheeks and glabella, with scattered erythematous indurated papules affecting the patient’s trunk, neck and limbs. Similar lesions in the scalp were observed, with associated alopecia. Mucous membrane involvement was present with nasal asymmetry, hard palate plaques and florid erythematous conjunctival nodules. No further multisystem involvement was noted on cardiovascular and endocrinology investigations. Treatment has been challenging due to underlying comorbidities and aggressive mucocutaneous disease. Cutaneous features responded to a combination of weaning oral prednisolone, hydroxychloroquine and methotrexate, healing with scarring. Flares have been exacerbated by cutaneous bacterial superinfection with Streptococcus pyogenes. Ocular disease remains recalcitrant, requiring lesional steroids. It has been four decades since the onset of the HIV/AIDS epidemic. Due to advances in pharmacotherapeutics, HIV has transitioned from a life-threatening infection to a chronic condition, bringing comorbidities into focus. Dermatological conditions are extremely common in HIV infection, and cutaneous IRIS manifestations account for up to 75% of all IRIS events. This IRIS manifestation is unique in its latent presentation, occurring months to years after HAART introduction – hypothesized to correlate with recovery of naive T cells. Clinically and histologically, presentations are similar to those of sarcoidosis occurring in patients with no HIV infection. However, comorbidities compounded with side-effects from immunosuppressants pose significant therapeutic obstacles in managing this challenging condition.
dermatology